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Burkitt-like lymphoma with 11q aberration is characterized by pathological features and 
gene expression profile resembling Burkitt lymphoma but lack MYC rearrangement and 
carries an 11q-arm aberration with proximal gains and telomeric losses. Whether these 
lymphomas are a distinct category or a particular variant of other recognized entities is 
controversial. To improve the understanding of Burkitt-like lymphoma with 11q 
aberration we have performed an analysis of copy number alterations and targeted 
sequencing of a large panel of B-cell lymphoma related genes in 11 cases. Most 
patients had localized nodal disease and a favorable outcome after therapy. 
Histologically, they were high grade B-cell lymphoma, not otherwise specified (8 
cases), diffuse large B-cell lymphoma (2 cases) and only one was considered as 
atypical Burkitt lymphoma. All cases had a germinal center B-cell signature and 
phenotype with frequent LMO2 expression. Burkitt-like lymphoma with 11q aberration 
had frequent gains of 12q12-q21.1 and losses of 6q12.1-q21, and lacked common 
Burkitt lymphoma or diffuse large B-cell lymphoma alterations. Potential driver 
mutations were found in 27 genes, particularly involving BTG2, DDX3X, ETS1, EP300, 
and GNA13. However, ID3, TCF3, or CCND3 mutations were absent in all cases. 
These results suggest that Burkitt-like lymphoma with 11q aberration is a germinal 
center derived lymphoma closer to high grade B-cell lymphoma or diffuse large B-cell 






Our knowledge of pediatric and young adults lymphomas has dramatically increased in 
the last years with the identification of several subtypes that predominantly occur in this 
subgroup of age.1-4 One of these recently recognized categories is Burkitt-like 
lymphoma with 11q aberration (BLL-11q) which morphological, phenotypic, and gene 
expression profile resemble Burkitt lymphoma (BL), but they lack MYC rearrangements 
by standard detection methods as fluorescence in situ hybridization (FISH). 
Alternatively, these tumors carry an 11q-arm aberration characterized by proximal 
gains and telomeric losses.4 In comparison with BL, these lymphomas seem to have 
more complex karyotypes, a certain degree of cytological pleomorphism, sporadically a 
follicular pattern and high incidence of nodal presentation.4,5 Very similar cases have 
also been reported in the post-transplant setting,6 although its incidence in other 
immunocompromised conditions as HIV is still unclear.7,8 
 
BLL-11q has been incorporated in the revised WHO classification as a provisional 
category1 because its precise taxonomy as a particular variant of BL, diffuse large B-
cell lymphoma (DLBCL) or a distinct form of high grade B-cell lymphoma (HGBCL) is 
still controversial.1,4-6,9-11 The clarification of the biological nature of this uncommon 
lymphoma subtype is clinically relevant due to increasing interest in defining the most 
appropriate management strategies for specific subtypes of lymphomas in pediatric 
and young adults patients.12 Recent DNA copy number alteration (CNA) and next-
generation sequencing (NGS) studies have provided a comprehensive catalog of 
genomic aberrations in BL and DLBCL that clearly distinguish these entities.13-17 In this 
study we have performed an integrated analysis of genomic and mutational alterations 
with a complete annotation of clinical and pathological features of BLL-11q with the 
goal of obtaining insights to refine the understanding of the pathogenesis and improve 





Sample selection and DNA/RNA extraction 
To identify BLL-11q cases we initially reevaluated the presence of MYC translocation in 
95 cases diagnosed as BL, atypical BL or HGBCL, not otherwise specified (NOS), in 
our Hematopathology Unit between 2000-2016. Three consultation cases from centers 
belonging to Sociedad Española de Hematología y Oncología Pediátricas (SEHOP) 
were also analyzed. Cases were reviewed by three pathologists (BG-F, EC, ESJ). DNA 
and RNA were extracted using standard protocols (Qiagen, Hilden, Germany). This 
study was approved by the Institutional Review Board of the Hospital Clinic of 
Barcelona. Informed consent was obtained from all patients in accordance with the 
Declaration of Helsinki. 
 
Immunohistochemistry and FISH 
Immunohistochemical analysis using a panel of antibodies detecting common B and T 
cell markers as well as LMO2 and MYC was performed and interpreted as previously 
reported (Online Supplementary Table S1).18,19 
MYC breaks and MYC/IGH fusions were analyzed by FISH using XL MYC BA Probe 
(Metasystems, Altlussheim, Germany) and LSI IGH/MYC/CEP 8 Tri-Color Dual Fusion 
Probe Kit (Vysis-Abbott, Abbott Park, IL) respectively. The 11q alteration was studied 
with a custom FISH probe using BAC clones (Invitrogen inc.) for proximal gains (RP11-
414G21-spectrum green) and terminal losses (RP11-629A20-spectrum red) combined 
with CEP11-spectrum aqua (Vysis-Abbott inc.). The FISH constellation in a normal 
case is characterized by two signals per probe, while the pattern corresponding to the 
11q gain/loss or gain/amplification/loss aberration would be two blue, three up to five 
green signals and one red signal. The probe was tested in an independent series of 8 
non-Hodgkin B-cell lymphomas and 4 MYC-negative HGBCL with lack of the 11q 




Copy number analysis 
DNAs were hybridized on Oncoscan FFPE or SNP array platform (ThermoFisher 
Scientific, Waltham, MA) and analyzed as described previously (Online 
Supplementary Methods).2 Published CN data on MYC-positive BL20 and DLBCL13 
were reanalyzed for comparison. 
 
Sequencing approaches 
The mutational status of 96 B-cell lymphoma related genes (Online Supplementary 
Table S2) was examined by target NGS in 10 BLL-11q cases and 4 MYC-negative 
11q-negative cases using a NGS SureSelect XT Target Enrichment System Capture 
strategy (Agilent Technologies, Santa Clara, CA) before sequencing in a MiSeq 
instrument (Illumina, San Diego, CA) (Online Supplementary Methods). Additionally, 
analysis of hotspots of mutation in ID3, TCF3 and CCND3 genes, ETS1 exon 1 
(transcript NM_005238) and verification of variants in specific cases was performed by 
Sanger sequencing using primers described in Online Supplementary Table S3. 
 
Gene expression analysis 
Cell of origin (COO) determination on Lymph2Cx assay (Nanostring, Seattle, WA) was 
performed as previously published.21 Gene expression levels of MYC and ETS1 were 
investigated by real time quantitative PCR (Online Supplementary Methods) using 
Taqman assays described in Online Supplementary Table S4. 
 
Statistical methods 
The χ2 method was used for categorical variables and Student’s t-test for continuous 
variables. Non-parametric tests were applied when necessary. The P-values for 
multiple comparisons were adjusted using the Benjamini–Hochberg correction. Survival 
curves were estimated by Kaplan-Meier method. Statistical analyses were carried out 




Identification of BLL-11q cases 
To identify BLL-11q cases we reevaluated the presence of MYC translocation in 95 
cases diagnosed as BL, atypical BL or HGBCL, NOS. We confirmed the presence of 
MYC rearrangements in 78 cases (82.1%), from which 67 (70.5%) were classified as 
BL. Since the 11q aberration has been found mainly in children and young adult (<40 
year-old) patients,4 we analyzed separately the 60 patients under 40 years and the 35 
older patients (Online Supplementary Figure S1). 
 
In the younger cohort (n=60), the 46 (76.7%) cases with MYC translocation were 
classified as BL. To find BLL-11q cases, we initially used the Oncoscan platform in the 
remaining 14 MYC-negative patients and detected the presence of the 11q gain/loss 
alteration in eight of those. Additionally, we found a CN pattern consistent with the 
presence of 11q alteration in 3 recent consultation cases from SEHOP (Online 
Supplementary Figures S1 and S2). Then, among those BLL-11q cases we could 
verify the presence of the 11q aberration by FISH in all 10 evaluable cases (Online 
Supplementary Figure S3 and Supplementary Table S5). Morphological, clinical, 
genetic features and consensus diagnosis of the 11 BLL-11q identified in our files are 
summarized in Table 1. The 6 cases negative for the MYC rearrangement and 11q 
aberrations by Oncoscan were re-classified as DLBCL (3 cases) or HGBCL, NOS (3 
cases). The DLBCL had predominant centroblastic morphology, germinal center 
phenotype, very high proliferative index and focal “starry sky” pattern (see Online 
Supplementary Results). The absence of 11q alterations was also verified using the 
11q FISH probe in 4 of these MYC/11q negative cases with evaluable material (Online 
Supplementary Figure S1A).  
 
In the 35 older (≥ 40 yr) patients, a MYC translocation was found in 32 cases; 1 was 
classified as DLBCL, 21 as BL, and 10 were HGBCL with double or triple hit (BCL2 
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and/or BCL6 translocations). Only 3 cases were negative for MYC translocations and 
were classified as HGBCL, NOS (Online Supplementary Figure S1B and 
supplementary Results). We screened these cases with the 11q FISH probe and the 
3 were negative for the 11q aberration. 
 
Clinical and morphological results of BLL-11q cases 
The 11 patients with BLL-11q had a mean age of 15 years (range 8-37); eight were 
male (Table 1). Eight tumors were reclassified morphologically as HGBCL, NOS, two 
as DLBCL and only one case was considered atypical BL. None of the cases were 
considered as typical BL (Figure 1). Six cases exhibited starry sky pattern and two had 
a nodular growth pattern with the presence of a disrupted follicular dendritic cell 
meshwork (Figure 1C). Ki67 was very high in all the samples, similar to BL. All cases 
had a germinal center (GC) phenotype and GCB signature by Nanostring Lymph2Cx 
assay. MUM1/IRF4 was negative in all 11 cases. One case expressed BCL2 (Figure 
1D). LMO2, a germinal center marker that is usually seen in GCB-DLBCL but not in 
BL18 was expressed in 5 cases (Figure 1A-B). Interestingly, using a 40% cut off,19 5 
cases were positive for MYC expression. However, only one case showed a diffuse 
and intense positivity meanwhile the other four cases had either only positivity in 
around 50% of the cells or the intensity was not the expected in typical BL. Additionally, 
MYC RNA levels were significantly lower in BLL-11q than in MYC-positive BL (relative 
expression 0.07 vs 0.36, P=0.019) (Online Supplementary Figure S4A). The Epstein-
Barr virus hybridization (EBER) was negative in the nine cases tested. 
Clinically, BLL-11q had frequent nodal localized presentation (8/11) in the head and 
neck region. Two cases had an extranodal presentation, one in the context of an acute 
appendicitis and the other debuted as an omental mass. Eight patients (73%) had 
stage I-II, and one patient presented in an advanced stage (IVAE) with widespread 
disease in the context of chronic HIV infection. All cases were treated with 
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chemotherapy, including Rituximab in five. All patients were alive with no disease after 
median follow-up of 30 months (Table 1).  
 
Copy number analysis 
The CN analysis of all the 11 BLL-11q cases showed a total of 78 alterations (Mean 
7.1; Range 2-15) (Online Supplementary Table S5 and S6). Seven cases had the 
typical 11q gain/loss pattern (Figure 2A-B, Online Supplementary Figure S2), two 
cases had only an 11q terminal deletion, one case showed a complex 11q alteration 
with two gains and two losses, and finally one case had an 11q23.3-q25 copy number 
neutral loss of heterozygosity (CNN-LOH) in addition to gain (Online Supplementary 
Figure S2). Two minimal regions of gain were identified (chr11:103326831-
111737912/11q22.3-q23.1 and chr11:114767237-116764582/11q23.3) whereas the 
minimal region of loss was depicted in chr11:128214400-132020453/11q24.3-q25 
(Including ETS1 and FLI1 genes). No cases with homozygous deletions of these two 
targets were observed in our series. The breakpoint region between gain and loss was 
not conserved and span from chr11:118352769 to chr11:121062860. Amplification in 
the 11q arm were observed in four cases, with a minimal region chr11:118347020-
120155799/11q23.3, including USP2 gene (Online Supplementary Figure S5). The 
most recurrent CNA other than 11q were 12q12-q21.1 gains and 6q12.1-q21 losses 
(Figure 2A). 
 
BLL-11q cases displayed similar levels of complexity than MYC-positive BL (7.1 vs 6 
alterations),20 but significantly lower than GCB-DLBCL (7.1 vs 19, P<0.0001).13 The 
BLL-11q genomic profile differed from that of BL and DLBCL (Online Supplementary 
Figure S6). BLL-11q had frequent gains of 5q21.3-q32 and losses of 6q12.1-q21 and 
lacked the 1q gains seen in MYC-positive BL. BLL-11q also lacked alterations typically 
seen in GCB-DLBCL such as gains of 2p16.1 and 7p and losses of 1p36.32.  
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The six tumors negative for both MYC and 11q-aberrations in patients younger than 40 
years had similar levels of genomic complexity than those observed in BLL-11q (7.01 
vs 11.83; P=0.16) (Online Supplementary Figure S7A). The unique significant 
aberration that distinguished the two groups was the presence/absence of the 11q 
aberration. 
The review of the literature regarding other lymphoid neoplasms confirmed that the 11q 
alteration observed in BLL-11q is mainly absent in other lymphoma entities with the 
exception of transformed follicular lymphoma (16%) (Online Supplementary 
Results).22 
 
NGS and gene expression analysis  
Target NGS showed a total of 49 potential driver mutations affecting 27 different genes 
(mean=4.9 mutations per case) (Figure 2C-D, Online Supplementary Figures S8 
and S9; Online Supplementary Table S7). Interestingly, all cases lacked the typical 
BL mutations in ID3, TCF3, or CCND3 genes, and their mutational profile was more 
similar to that of other GC derived lymphomas with recurrent mutations affecting BTG2 
(4 cases), DDX3X, ETS1, EP300, and GNA13 (3 cases each) (Online Supplementary 
Table S8). Five cases had mutations in epigenetic modifiers genes such as EP300, 
CREBBP, KMT2C, EZH2, ARID1A, KMT2D, HIST1H1D and HIST1H2BC. Two cases 
had concomitant TMEM30A deleterious mutations associated with 6q14.1 deletion as 
seen in DLBCL but not in BL (Figure 2C).14-16 
 
BTG2 mutations found in 4 cases were 3 missense and 1 deletion in a splicing site. 
BTG2 is a tumor suppressor gene with an important role in G1/S transition through 
inhibition of CCND1 in a pRb-dependent mechanism.23 These BTG2 inactivating 
mutations could release CCND1 inhibition and accelerate G1/S transition. GNA13 
mutations were found in 3 cases including 4 missense, 2 nonsense, and 1 missense 
mutation in a splicing site. Two MYC missense mutations occurred in the central 
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domain of the protein, but did not affect threonine phosphorylation sites (Online 
Supplementary Table S7).24 ETS1 mutations have been previously described in BLL-
11q and ABC-DLBCL13,17 but not in conventional BL (Online Supplementary Table 
S8).14,15 We detected 3 coding mutations located on the winged helix-turn-helix DNA-
binding domain but the previously described exon 1 mutations (NM_005238) were 
absent in this series. ETS1 RNA expression was lower in BLL-11q than MYC-positive 
BL (relative expression 6.6 vs 19.3, p< .001) and was also lower in ETS1 mutated than 
wild-type BLL-11q (relative expression 1.9 vs 8.6, P=0.03) (Online Supplementary 
Figure S4B).  
 
The mutational profile of 4 MYC-negative/11q alteration-negative cases with material 
available was analyzed using the same approach. No mutations in BTG2, EP300 or 
ETS1 genes were observed. Moreover, three out of four did not harbor any BL-related 
mutation on ID3, TCF3 and CCND3 whereas the fourth case had a mutational profile 
commonly seen in BL with MYC, DDX3X, SMARC4, CCND3 and TP53 mutations 





BLL-11q was initially recognized as a particular subset of HGBCL that had an 
expression profile and some pathological characteristics similar to BL but lacked MYC-
translocations and alternatively shared a common pattern of gains at 11q23 associated 
with losses at 11q24-qter. The particular features of these cases raise some 
uncertainty on their precise categorization as a variant of BL or a tumor related to other 
HGBCL.1,4-6,9-11 On the other hand, the limited number of cases reported and the 
different methodologies used for their recognition do not provide a clear view of their 
incidence and clinico-pathological characteristics.     
 
In this study we have searched our files for cases that could be reclassified as BLL-11q 
among 95 tumors previously classified as BL, atypical BL, or HGBCL, NOS and found 
8 (8%) cases with the chromosomal aberration. These cases together with 3 additional 
cases received on consultation were investigated for the copy number alteration CNA 
and mutational profiles and compared to the genomic aberrations recently identified in 
BL, DLBCL, and HGBCL.13-17 BLL-11q had similar levels of complexity as MYC-positive 
BL,20 but significantly lower than GCB-DLBCL.13 The BLL-11q genomic profile differed 
from that of BL and DLBCL (Online Supplementary Figure S6). BLL-11q had frequent 
gains of 5q21.3-q32 and losses of 6q12.1-q21 and lacked the 1q gains seen in MYC-
positive BL. BLL-11q also lacked alterations typically seen in GCB-DLBCL such as 
gains of 2p16.1 and 7p and losses of 1p36.32. Additionally, we identified a mutational 
profile in BLL-11q different from that of MYC-positive BL since all cases lacked the 
typical BL mutations in ID3, TCF3, or CCND3 genes and had mutations in BTG2, 
DDX3X, ETS1 not seen in BL. In addition, BLL-11q had mutations in epigenetic 
modifier genes such as EP300, CREBBP, KMT2C, EZH2, ARID1A, KMT2D, 
HIST1H1D and HIST1H2BC that are common in DLBCL, particularly of the GC 
subtype. Other genes frequently mutated in GC-DLBCL but not in BL were GNA13 and 




We also compared our results with two recent studies on HGBCL (including double and 
triple hit lymphomas).25,26 These cases have also recurrent mutations on histone 
modifier genes such as KMT2D, CREBBP or EZH2 (Online Supplementary Table 
S8). Intriguingly, HGBCL, NOS, mainly with MYC-translocations, shared mutations in 
genes frequently mutated in both BL and GC-DLBCL.25,26 All these observations 
suggest that BLL-11q is a neoplasm closer to other GC-derived lymphomas rather than 
BL in which the 11q aberration together with other mutations may play a relevant role in 
their pathogenesis. Whereas this manuscript was on revision, Wagener et al published 
a mutational study of 15 BLL-11q. Similar to our findings, no mutations in ID3/TCF3 
were found and those cases carried frequent mutations in GC-DLBCL associated 
genes such as GNA13, FOXO1 and EZH2. Intriguingly, this study did not find 
mutations in BTG2, KMT2D, KMT2C or CREBBP observed in our study.27 All together 
these findings indicate that the genomic and mutational profile of BLL-11q is different 
from those of BL and more similar to other GC derived lymphomas. 
 
In addition to the genetic differences, our BLL-11q differed clinically, morphologically 
and phenotypically from conventional BL and instead showed features more consistent 
with HGCBL or DLBCL. As in previous studies, all our patients were younger than 40 
years, although occasional cases in older patients have been reported.4,5,27 Contrary to 
BL, BLL-11q presented with localized lymphadenopathy in most of our cases.4,5,27 
These cases have a favorable outcome after therapy, although the optimal clinical 
management remains to be determined. Morphologically, our cases had a prominent 
“starry sky” pattern and high proliferation (>90%) but did not have the typical cytological 
features of BL since they were better classified as HGBCL with blastoid or intermediate 
features between HGBCL (8 cases) and DLBCL (2 cases) and only one had features of 
atypical BL. As previously reported,4 two of our cases displayed a follicular growth 
pattern, with an underlying meshwork of follicular dendritic cells, raising the differential 
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diagnosis with other pediatric lymphomas such as large B-cell lymphoma with IRF4 
rearrangement.3 However, BLL-11q do not express IRF4/MUM1 and frequently 
exhibited a starry sky pattern with frequent mitotic figures, features that are not usual in 
large B-cell lymphoma with IRF4 rearrangement. We also identified different 
immunohistochemical stainings that could help in the differential diagnosis with other 
lymphomas entities. LMO2, a germinal center marker that is typically downregulated in 
BL and other lymphomas with MYC translocation,18 is detected in 46% of our BLL-11q. 
In addition, and contrary to BL, MYC expression with a diffuse and intense pattern was 
only detected in one of our cases while the other four positive cases either exhibited 
partial positivity or the intensity was weak contrary to the pattern seen in BL.  
 
The negativity for MYC rearrangement is a crucial element for the recognition of these 
cases. The recommended technique for interrogating MYC translocations in the clinical 
practice is the FISH analysis using break-apart probes, with the limitation that a subset 
of 4% of MYC positive cases are not detected with this method but picked up using 
MYC/IGH probes.28 The genetic feature that distinguishes BLL-11q is an alteration of 
the 11q arm that prototypically is characterized by an 11q23.2-q23.3 gain/amplification 
and 11q24.1-qter loss. Additionally, isolated cases have been recognized with single 
11q24.1-qter terminal loss or 11q23 gain with 11q24 CNN-LOH.4,11 In our study we 
have identified the presence of these 11q alterations using CN array. We also 
confirmed the presence of 11q alterations by FISH analysis with a custom probe in all 
tested cases, suggesting that this approach may be useful in the clinical practice to 
identify these cases (Online Supplementary Table S8). The specificity of this FISH 
approach was also confirmed by the fact that no false positive cases were observed in 
the 12 lymphoma cases in which the array showed a normal 11q pattern. Nevertheless, 
more studies on the clinical value of this probe are needed and, for the time being, 
confirmation of the finding by CN array would be desirable. The specific 11q alteration 
observed in BLL-11q should be distinguished from other 11q aberrations such as 11q 
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gains of the 11q24 region that include ETS1 and FLI1 detected in DLBCL 29 or the 
11q25 losses missing ETS1 and FLI1 described in some post-transplant 
lymphoproliferative disorders.30,31 On the other hand, although the 11q23 gain/11q24-
qter loss of BLL-11q is mainly absent in other lymphoma entities, its detection should 
not be considered as a unique tool to diagnose BLL-11q cases since some transformed 
FL may carry a similar 11q aberration pattern.22  
 
In summary, BLL-11q is a germinal center derived lymphoma with a genomic and 
mutational profile closer to HGBCL or GC-DLBCL rather than BL in which the 11q 
aberration, together with other mutations, may play a relevant role in their 
pathogenesis. These observations support a reconsideration of the “Burkitt-like” term 
for these tumors. Although, the most appropriate name is not easy to propose and 
requires broader discussion and consensus, we think that the term “aggressive B-cell 
lymphoma with 11q aberration” captures their pathological features. To identify these 
cases we suggest performing CN arrays or FISH with the 11q probe in cases with BL, 
DLBCL, and HGBCL morphology, germinal center phenotype and very high 
proliferative index (>90%), without MYC rearrangements, in young patients. The 
recognition of these tumors is clinically relevant because they have a favorable 
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gender diagnosis  diagnosis follow-up 
     CD10& BCL6  
IRF4/ 
MUM1 BCL2   LMO2    MYC    
  




NOS + - - - + I GCB A Yes CR, 72m 




DLBCL + - - + - IV-E GCB A Yes CR, 112m 




+ - - - - II GCB P No CR, 54m 
#4 17,F Submaxilar LN HGBCL 
HGBCL, 
NOS + - - + + I GCB A Yes CR, 22m 






+ - + + - I GCB P No CR, 29m 
#6 14,M Appendix HGBCL DLBCL + - - + - II GCB P No CR, 25m 
#7 8, M Laterocervical LN BL Atypical BL + - - - - I GCB P No CR, 113m 
#14 8,M Laterocervical LN BL 
HGBCL  
blastoid  + - - - 
Weak 





NOS + - - - + I GCB P No CR, 35m 




+ - - + - III GCB P Yes CR, 12m 
#17 16, M Omentum HGBCL HGBCL, NOS + - - - + III GCB A Yes CR, 4m 
 Abbreviations: M: male; F: Female; LN: Lymph node; BL: Burkitt Lymphoma; HGBCL: High grade B-cell lymphoma; NOS: Not otherwise specified; DLBCL: Diffuse Large B-cell lymphoma; Epstein-Barr virus in situ 
hybridization (EBER) were negative in all 9 tested cases. E: extranodal; COO: Cell of origin; GCB: Germinal center B-cell; A: Adult schema protocol (R-CHOP or Burkimab); P: pediatric schema protocol. All patients 
received CNS prophylaxis 





Figure 1. Morphological features of Burkitt-like lymphoma with 11q aberration 
cases. (A1-A3) Case #2 shows typical DLBCL morphology with large and irregular cells 
resembling centroblasts. This case was positive for (A2) LMO2 and negative for (A3) 
MYC. (B1-B3) Case #4 corresponds to a tumor with HGBCL morphology. It is composed 
mostly medium-sized cells with mild heterogeneity. Notice the “starry sky” pattern. This 
case was positive for (B2) MYC and (B3) LMO2 expression. (C1-C2; case #7) Lymph 
node with nodular architecture and “starry sky” pattern with large follicles and disrupted 
follicular cell meshwork highlighted with (C2) CD21. (D1-D2; case #5) shows a case with 
HGBCL features with expression of (D2) BCL2 in the neoplastic cells.  
 
Figure 2. Genetic features of Burkitt-like lymphoma with 11q aberration cases. (A) 
Global copy number profile of the 11 Burkitt-like lymphomas with 11q aberration. X-axis 
indicates chromosomes from 1 to Y and p to q. The vertical axis indicates frequency of the 
genomic aberration among the analyzed cases. Gains are depicted in blue, losses are 
depicted in red. (B) Individual CN profile of case #16 showing a prototypical, gain, loss 
and amplification in the 11q region. Each probe is aligned from chromosome 1 to Y and p 
to q arm. (C) Mutational overview of 10 BLL with 11q aberration. The heat map shows the 
case specific pattern of driver mutations found by next generation sequencing. Each 
column represents a case and each row represents a gene. The right bar graph illustrates 
the mutation frequency of each gene. (D) A diagram of the relative positions of driver 
mutations is shown for BTG2, ETS1 and GNA13 genes. Domains BTG2: BTG family 
domain. Domains ETS1: PNT: Pointed domain; TAD: transactivation domain; H-1/2: 
inhibitory α-helices 1/2; DBD: DNA binding domain; H4-5: α-helix 4/5. Domains GNA13: 
G-alpha: G protein alpha subunit. Circles indicate missense mutations, triangles indicate 
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Copy number analysis 
DNAs were hybridized on Oncoscan FFPE or SNP array platform (ThermoFisher 
Scientific, Waltham, MA). Gains and losses and copy-number neutral loss of 
heterozygosity (CNN-LOH) regions were evaluated and visually inspected using Nexus 
Biodiscovery version 9.0 software (Biodiscovery, Hawthorne, CA). Human reference 
genome was GRCh37/hg19. The copy number alterations (CNAs) with minimum size 
of 100 kb and CNN-LOH larger than 5 Mb were considered informative. Physiological 
deletions of the immunoglobulin loci were excluded from the analysis. T-cell receptor 
locus deletions were also excluded, most probably representing physiological deletions 
of accompanying reactive T cells. Copy number data are deposited at GEO database 
GSE116527. Published CN data on MYC-positive BL1 were reanalyzed. 
 
Library preparation SureSelect XT and Targeted sequencing approach 
DNA and RNA were extracted using standard protocols from formalin fixed paraffin 
embedded material in 12 and frozen tissue in 3 cases (Qiagen, Hilden, Germany). 
A total of 100ng of genomic DNA was sheared using the Covaris S220 focused-ultra 
sonicator (Covaris, Woburn, MA) to a target peak size of 150–200 bp. Library 
preparation were performed using SureSelectXT Custom Capture Library baits as 
described in SureSelectXT Target Enrichment System protocol (Agilent Technologies, 
Santa Clara, CA). For amplification of the post capture libraries, 10 to 13 cycles were 
performed depending on the initial sample quality. The libraries were qualified using 
the Bioanalyzer HS (Agilent technologies), quantified with the KAPA Library 
Quantification Kit (Kapa Biosystems, Wilmington, Massachusetts) and sequenced in a 
MiSeq instrument (Illumina, San Diego, CA) in a paired-end run of 150 bp. The average 
sequencing coverage of 10 Burkitt-like lymphoma with 11q (BLL-11q) cases across 
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regions was 478x (range 97-1229) and over 93% of the targeted regions were covered 
by at least 100 reads. (Supplementary Figure S7). 
FASTQ files were generated by MiSeq control software and quality control of the raw 
data was performed using the FastQC tool 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Sequencing reads were 
subsequently aligned to the human reference genome (GRCh37/hg19) using the 
Burrows-Wheeler Aligner–MEM algorithm.2 Variant calling was performed using two 
different variant callers: Somatic Variant Caller (Illumina) and annotated using the 
VariantStudio software v3.0 and Mutect2 (Genome Analysis Toolkit (GATK), version 
4.0.3)3 and annotated by ANNOVAR.4 We used Somatic Variant Caller (Illumina) with 
the default settings to analyze sequencing results and to call the variants. Low quality 
or low coverage calls (total depth <20) were excluded. For Mutect2 variants, low quality 
variants were also excluded using FilterMutectCalls (GATK) with default thresholds. 
Only variants identified by both algorithms were considered. For further analysis we 
excluded all synonymous and intron variants outside splicing sites (not included in the 
panel, with exception of intron 1 of MYC) and known polymorphisms described in the 
Single Nucleotide Polymorphism Database (dbSNP138) or ExAC database (release 
2015) with more than 0.1% frequency according to the corresponding ethnicity. Finally, 
each variant was also inspected with the Integrative Genomics Viewer (IGV, Broad 
Institute, version 2.3) software to exclude artifacts. 
 
Prediction of mutation effect 
Since there was no germline DNA available, in order to select somatic variants, 
potential driver mutations were predicted according to previously published criteria5 in 
which the 90% of the mutations classified as functional were demonstrated to be 
somatic (Supplementary Table S7). Inclusion criteria were: 1) any variant described 
previously as somatic or functional on previous reports or COSMIC, 2) All truncating 
variants (nonsense, frameshift, splice donor or acceptor mutations; and 3) the 
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remaining missense variants that were predicted to be functionally deleterious using 
Mutation Assessor6 and SIFT7 predictors. Other predictors as Polyphen-2 
(Polymorphism Phenotyping-2)8 and CADD (Combined Annotation Dependent 
Depletion)9 were also used. 
 
Quantitative PCR 
Gene expression levels of MYC and ETS1 of 10 BLL-11q with RNA available and 12 
conventional MYC-positive BL were investigated by real time quantitative PCR (qPCR) 
as described previously.10 Complementary DNA synthesis was carried out from 500 ng 
of total RNA and the product was amplified and quantified using TaqMan Universal 
PCR Master Mix no AmpErase UNG (Thermo Fisher Scientific Inc.), designed primer 
sets, and TaqMan Gene Expression Assays for MYC (Hs00153408_m1) and ETS1 
(Hs00428293_m1) (Thermo Fisher Scientific Inc.).  
DNA was analyzed using duplicates in a StepOne Plus Real-Time PCR System 
(Thermo Fisher Scientific Inc.). Relative quantification of gene expression was then 
analyzed with the 2-Ct method using B2M (Hs00939627_m1), as the endogenous 
control gene, and Universal Human Reference RNA (Stratagene, Agilent Technologies, 
Santa Clara, CA, USA), composed of total RNA from 10 human cell lines, as the 
mathematical calibrator.  
 
Supplementary Results 
Morphological features of 9 MYC-negative, 11q-negative lymphoma cases  
Among the 95 cases with an initial diagnosis of BL, atypical BL or high grade B-cell 
lymphoma, not otherwise specified (HGBCL,NOS) nine (9.5%) were negative for MYC 
rearrangements, using both the break-apart and the double fusion probes (only seven 
cases analyzed), and for the 11q alteration. After the morphological review three cases 
were better reclassified to diffuse large B-cell lymphoma (DLBCL). These cases were 
composed of a proliferation of centroblastic cells with starry sky pattern, germinal 
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center phenotype and very high proliferative index. One case was weakly positive for 
BCL2. The remaining 6 cases had HGBCL, NOS morphology, two of them with blastoid 
features. Four cases had a germinal center phenotype and BCL2 negativity and two 
cases had an activated phenotype with BCL2 positivity. All cases had a proliferative 
index close to 100%. 
 
Comparison of Copy number profile of BLL-11q with other lymphoma entities 
BLL-11q lymphoma had similar levels of genomic complexity as conventional MYC-
positive BL with 7.1 vs. 6 alterations, respectively. However, gains of 5q21.3-q32 and 
losses of 6q12.1-q21 were virtually exclusive of BLL-11q whereas 1q gains were only 
seen in MYC-positive BL. In comparison to the two molecular DLBCL subtypes, BLL-
11q cases displayed significantly lower levels of complexity than ABC and GCB-DLBCL 
(7.1 vs. 22 alterations in ABC and 19 alterations in GCB; both P<0.001), had the 
specific 11q alterations and lacked gains of 2p16.1 and 7p and losses of 1p36.32 
associated with GCB phenotype and losses of 6q23.3, 9p21.3 and 17p13.2 related to 
ABC-DLBCL. 
To determine the specificity of the 11q-gain/loss pattern in BLL-11q in comparison to 
lymphoid neoplasms other than BL and DLBCL, we screened previously published data 
considering both patterns of prototypical pattern of gain followed by loss or only the 
presence of terminal 11q24.3-q25 loss. Frequencies observed were less than 1% in all 
the reviewed entities including follicular lymphoma,11 nodal marginal zone lymphoma,12 
chronic lymphocytic leukemia13 or plasma cell myeloma14,15 with exception of 
transformed follicular lymphoma11 in which 16% cases, presented the 11q aberrations. 
These data suggest that this alteration is mainly absent in other recognized lymphoma 




Supplementary Figure S1. Diagram of the strategy used for the identification of 
Burkitt-like with 11q aberration in a cohort of (A) 60 patients <40 years old and (B) 35 
patients ≥ 40 years old with a morphological diagnosis of Burkitt lymphoma 
(BL)/atypical BL and high grade B-cell lymphoma, not otherwise specified (HGBCL, 
NOS) according to the updated WHO Classification 2016.16 Seven out of nine cases 
negative for both MYC and 11q alterations with material available were tested by 
MYC/IGH double color double fusion probe, and all resulted to be negative for the 
fusion. Abbreviations: DLBCL, diffuse large B-cell lymphoma; DHL, double hit 






 Supplementary Figure S2. Individual and integrative copy number plots of (A) 
eleven Burkitt-like with 11q and (B) six MYC-negative 11q-negative lymphoma cases. 
The vertical axis indicates frequency of the genomic aberration among the analyzed 
cases. Gains are depicted in blue, losses are depicted in red, and regions of CNN-LOH 




Supplementary Figure S3. Representative 11q aberration by FISH. (A) FISH image 
of a representative case (#17) harboring 11q aberration using a custom probe 
combining CEP11 (Spectrum Aqua), RP11-414G21 (Spectrum Green) and R11-
629A20 (Spectrum Red) bac clones. (B) Two blue signals are observed per cell 
corresponding to the two chr11 centromeres, (C) the presence of three green signals 





Supplementary Figure S4. MYC and ETS1 RNA expression levels in BLL-11q. (A) 
Box plot of the percentage of MYC expression analyzed by qPCR in BLL-11q (n=9) 
vs. MYC-positive BL (n=9). (B) Box plot of the percentage of ETS1 expression 
analyzed by qPCR in BLL-11q (n=10) vs. MYC-positive BL (n=12). The significance 





Supplementary Figure S5. Ideogram of chromosome 11q arm of 11 MYC-negative 
cases harboring 11q aberration by CN array. Gains are represented in blue, red 
corresponds to losses and CNN-LOH are represented in yellow. Two minimal regions 
of gain (MRGs) and one minimal region of loss (MRL) are pointed with blue and red 





Supplementary Figure S6. Comparative plot of copy number aberrations between 
Burkitt-like lymphoma with 11q aberration (n=11) and (A) conventional MYC-positive 
Burkitt Lymphoma (n=35),1 (B) GCB-Diffuse Large B-cell lymphoma (n=45)5 and (C) 
ABC-Diffuse Large B-cell lymphoma (n=49)5 X-axis depicts chromosome positions with 
dotted lines pointing centromeres. Y-axis indicates frequency of the genomic aberration 
among the analyzed cases. Significantly different regions of alterations among groups 





Supplementary Figure S7. (A) Comparative plot of copy number aberrations between 
Burkitt-like lymphoma with 11q aberration (n=11) and 6 MYC-negative 11q-negative 
cases (B) Mutational overview of 4 MYC-negative 11q negative cases in comparison 
with BLL with 11q aberration. The heat map shows the case specific pattern of driver 
mutations found by next generation sequencing. Each column represents a case and 








Supplementary Figure S8. Mean coverage distribution per gene of the 10 BLL-11q 
cases analyzed by target NGS. Y-axis indicates the mean number of reads. The red 
line depicts the mean coverage of all 10 cases. DNA from #2, #4 and #7 BLL-11q 





Supplementary Figure S9. NGS analysis pipeline followed to identify potential driver 
mutations in 10 BLL-11q samples. Two different variant callers were used: Somatic 
Variant Caller (Illumina) and Mutect2 (GATK version 4.0.3) and potential driver 
mutations were predicted according to previously published criteria.5 SIFT predictor 











Supplementary Table S1. Details of all antibodies used, source and conditions of use.  
 





EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
CD79a JCB 117 DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
CD3 Polyclonal DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
CD5 4C7 DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
CD10 56C6 DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
BCL6 PG-B6p DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
BCL2 124 DAKO EDTA 1 mM pH 9/ ENVISION FLEX (DAKO) RTU 
Ki67 Mib-1 DAKO Citrate 10 mM pH 6/ ENVISION FLEX (DAKO RTU 
MUM1 MRQ-43 
Ventana, Roche 
CC1 solution / ultraView Universal DAB Detection 





CC1 solution / ultraView Universal DAB Detection 








CC1 solution / ultraView Universal DAB Detection 




RTU, ready to use. 
*LMO2 was considered positive when >30% of the cells were positive and MYC was considered positive when 





Supplementary Table S2. Ninety-six genes sequenced using Target NGS panel 
including references for inclusion in the mutational analysis and mean coverage by 
gene and amplicon. 
Provided in excel format 
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Supplementary Table S3. Primers used for the verification of variants in MYC, BTG2, 
ETS1 and TP53 and the re-analysis of ID3, TCF3 (exon 17) and CCND3 (exon 5).  
Primers ETS1 







ETS1_1 F CTGCAGGTCACACACAAAGC 157 BLL2 T>T/C 128332392 
ETS1_1 R TAAATTTCAGGTGGCCAGGA  BLL7 C>C/T 128332410 
        
ETS1_5 F CCACGGCTCAGTTTCTCATA 168 BLL2 A>A/T 128332477 
ETS1_5 R GGGTCACCATGAATGGGTAT 
 
   
        
ETS1_3 F TTTGAATTCCCAGCCATCTC 167 BLL14 G>G/A 128333508 
ETS1_3 F GTGGGGATTAGCTGCGTAGA 
 
   
    
 
   
ETS1_E1F GAAAGGGGGAAGAAGTCCAG 
200  Exon 1 of transcript 
M_005238   
ETS1_E1R CAAACTTGCTACCATCCCGTA 
 
   
  
 
   
Primers BTG2 









BLL1 C>C/T 203274858 
BTG2_1R CTGCCGCAGGAGTAGAAGAA 
 
BLL2 G>G/A 203274867 
    
 
BLL7 del 203274878 
    
 
   
Primers MYC 







MYC_2 F GAGCTGCTGGGAGGAGACAT 150 BLL7 T>T/G 128750921 
MYC_2 R CTGGTAGGAGGCCAGCTTCT     
        
MYC_4 F CTCCTGGCAAAAGGTCAGAG 158 BLL1 C>C/G 128752800 
MYC_4 R CCTCTTGGCAGCAGGATAGT 
 
   
  
 
   
Primers TP53 







TP53_2 F CCAGTGTGATGATGGTGAGG 163 BLL4 C>C/T 7577538 
TP53_2 R CCTGCTTGCCACAGGTCT     
      
      
      
      
      
      








    
ID3-FZ-F TCCAGGCAGGCTCTATAAGTG 694 Rohde, et al19     
ID3-FZ-R CCGAGTGAGTGGCAATTTTT  Rohde, et al
19     
          
ID3-PE-F  GCTTACCTGGATGGGAAGGT 204      
ID3-PE-R   GAGGAGCCGCTGAGCTTG       
      
Primers TCF3 




    
TCF3-FZ-F   
TGCTGTGCCCACCAATGTAAG
CCATG 
609 Rohde, et al19 
    




Rohde, et al19     
    
 
     
TCF3-PE-F  CAGGATGAGCAGCTTGGTCT 180      
TCF3-PE-R   AGTACGGACGAGGTGCTGTC       
      
Primers CCND3 




   
CCND3-FZ-F   CCATGTGTTGGGAGCTGTC 328 Rohde, et al19     
CCND3-FZ-R   CTGGAGGCAGGGAGGTG 
 
Rohde, et al19     
    
 
     
CCND3-PE-F   GCCCCTCCTCTGCTTAGTG 198      
CCND3-PE-R   CTGTCAGGAGCAGATCGAAG         
      





Supplementary Table S4. Taqman assays used for qPCR analyses. (Applied Biosystems 
inc)   
Amplicon size Reference 
Gene Symbol Assay ID (bp) sequence 
ETS1 Hs00428293_m1 99 NM_005238 
MYC Hs00153408_m1 107 NM_002467 








Supplementary Table S5. Summary of copy number findings and FISH pattern constellation of the 11q 
aberration in the current series of BLL-11q. 
Case CN array 11q FISH (CEP11 [D11Z1] + RP11-414G21+RP11-629A20) 
 Pattern of chr11 
Number of 
alterations 
11q FISH constellation pattern20 11q FISH result 
#1 Only terminal loss 2 CNA 
nuc ish (D11Z1x2,RP11-
414G21x2,RP11-629A20x1) 
Only terminal loss 
#2 Gain/terminal loss 3 CNA 
nuc ish (D11Z1x2,RP11-
414G21x2,RP11-629A20x1) 
Only terminal loss 
#3 Gain/terminal loss 





















#6 Only terminal loss 




Only terminal loss 




#14 Gain/terminal loss 4 CNA 
nuc ish (D11Z1x2,RP11-
414G21x2,RP11-629A20x1) 
Only terminal loss 
#15 Gain/terminal loss 
12 CNA + 1CNN-
LOH 

















CNA: copy number alteration. CNN-LOH: copy number neutral loss of heterozygosity. *Only observed in a few cells. CN 
and FISH results were not concordant in cases #2, and #14 most likely due to the fact that gained region covered by BAC 
RP11-414G21 was most likely inverted and then both copies were very narrow to be clearly distinguished as independent 






Supplementary Table S6. Global table of copy number and copy number neutral of heterozygosity 
(CNN-LOH) alterations of the 11 BLL-11q aberration and the 6 MYC-negative 11q-negative cases. 




#1           
  Oncoscan chr6:67,759,432-110,118,776 CN Loss 42359345 q12 - q21 
  Oncoscan chr11:124,440,617-132,877,670 CN Loss 8437054 q24.2 - q25 
#2           
  Cytoscan chr6:302,273-3,157,193 CN Gain 2854921 p25.3 - p25.2 
  Cytoscan chr11:66,015,813-120,252,657 CN Gain 54236845 q13.2 - q23.3 
  Cytoscan chr11:120,253,875-135,006,516 CN Loss 14752642 q23.3 - q25 
#3           
  Oncoscan chr5:1-180,915,260 CN Gain 180915260 p15.33 - q35.3 
  Oncoscan chr11:103,326,831-111,737,912 CN Gain 8411082 q22.3 - q23.1 
  Oncoscan chr11:111,747,297-113,562,039 CN Loss 1814743 q23.1 - q23.2 
  Oncoscan chr11:114,767,237-116,764,582 CN Gain 1997346 q23.3 
  Oncoscan chr11:127,681,132-132,020,453 CN Loss 4339322 q24.2 - q25 
  Oncoscan chr17:40,114,049-81,195,210 CNN-LOH 41081162 q21.2 - q25.3 
  Oncoscan chr18:20,935,833-78,007,784 CN Gain 57071952 q11.2 - q23 
#4           
  SNP6 chr3:148,377,370-198,022,430 CN Gain 49645061 q24 - q29 
  SNP6 chr4:151,106,726-151,889,624 CN Loss 782899 q31.3 
  SNP6 chr6:62,787,661-63,773,155 CN Loss 985495 q11.1 - q12 
  SNP6 chr6:66,807,178-136,034,966 CN Loss 69227789 q12 - q23.3 
  SNP6 chr6:137,582,049-168,332,407 CN Loss 30750359 q23.3 - q27 
  SNP6 chr6:168,596,580-171,115,067 CN Loss 2518488 q27 
  SNP6 chr8:118,905,307-134,171,629 CN Gain 15266323 
q24.11 - 
q24.22 
  SNP6 chr11:77,429,089-117,851,837 CN Gain 40422749 q14.1 - q23.3 
  SNP6 chr11:117,851,837-120,155,799 High Copy Gain 2303963 q23.3 
  SNP6 chr11:120,155,799-135,006,516 CNN-LOH 14850718 q23.3 - q25 
  SNP6 chr12:40,494,911-93,085,645 CN Gain 52590735 q12 - q22 
  SNP6 chr12:93,085,646-95,374,851 CN Loss 2289206 q22 
  SNP6 chr12:95,374,851-96,373,225 CN Gain 998375 q22 - q23.1 
  SNP6 chr18:29,031,540-56,749,287 CN Gain 27717748 q12.1 - q21.32 
  SNP6 chr18:56,749,288-78,077,248 CN Loss 21327961 q21.32 - q23 











#5           
  Oncoscan chr6:78,975,348-114,942,024 CN Loss 35966677 q14.1 - q22.1 
  Oncoscan chr11:83,088,730-117,240,357 CN Gain 34151628 q14.1 - q23.3 
  Oncoscan chr11:117,242,677-120,392,430 High Copy Gain 3149754 q23.3 
  Oncoscan chr11:120,398,613-134,938,847 CN Loss 14540235 q23.3 - q25 
#6           
  Oncoscan chr1:150,029,936-151,599,267 High Copy Gain 1569332 q21.2 - q21.3 
  Oncoscan chr1:151,744,168-249,212,878 CNN-LOH 97468711 q21.3 - q44 
  Oncoscan chr3:117,248,700-124,701,188 CNN-LOH 7452489 q13.31 - q21.2 
  Oncoscan chr3:177,647,728-197,852,564 CN Gain 20204837 q26.32 - q29 
  Oncoscan chr4:124,989,820-147,017,448 CNN-LOH 22027629 q28.1 - q31.22 
  Oncoscan chr5:38,139-5,124,613 CNN-LOH 5086475 p15.33 - p15.32 
  Oncoscan chr5:76,061,256-96,465,623 CNN-LOH 20404368 q13.3 - q15 
  Oncoscan chr5:171,201,195-180,698,312 CNN-LOH 9497118 q35.1 - q35.3 
  Oncoscan chr8:79,796,337-94,671,697 CNN-LOH 14875361 q21.12 - q22.1 
  Oncoscan chr9:204,738-10,275,857 CNN-LOH 10071120 p24.3 - p23 
  Oncoscan chr11:70,045,922-106,288,554 CNN-LOH 36242633 q13.3 - q22.3 
  Oncoscan chr11:128,214,400-134,938,847 CN Loss 6724448 q24.3 - q25 
  Oncoscan chr12:189,400-133,818,115 CN Gain 133628716 p13.33 - q24.33 
  Oncoscan chr13:91,639,578-92,147,712 CN Gain 508135 q31.3 
  Oncoscan chr14:54,084,642-76,110,632 CNN-LOH 22025991 q22.1 - q24.3 
  Oncoscan chr18:59,650,717-62,178,511 CN Gain 2527795 q21.33 - q22.1 
  Oncoscan chr18:55,902,055-66,218,776 CNN-LOH 10316722 q21.31 - q22.1 
#7           
  Cytoscan chr1:5,195,097-7,019,203 CN Loss 1824107 p36.32 - p36.31 
  Cytoscan chr3:60,388,322-60,712,277 CN Loss 323956 p14.2 
  Cytoscan chr5:104,762,975-174,135,222 CN Gain 69372248 q21.3 - q35.2 
  Cytoscan chr5:178,688,093-180,719,789 CN Gain 2031697 q35.3 
  Cytoscan chr11:72,390,640-72,717,317 High Copy Gain 326678 q13.4 
  Cytoscan chr11:72,717,332-119,682,209 CN Gain 46964878 q13.4 - q23.3 
  Cytoscan chr11:119,682,255-134,938,470 CN Loss 15256216 q23.3 - q25 














#8           
  Oncoscan chr1:23,506,625-23,985,309 CN Loss 478685 p36.12 - p36.11 
  Oncoscan chr1:116,776,586-118,300,350 CN Loss 1523765 p13.1 - p12 
  Oncoscan chr1:189,763,755-200,583,380 CN Gain 10819626 q31.1 - q32.1 
  Oncoscan chr2:180,790,820-198,749,269 CN Gain 17958450 q31.3 - q33.1 
  Oncoscan chr6:204,909-57,305,822 CN Gain 57100914 p25.3 - p11.2 
  Oncoscan chr6:57,329,886-58,055,927 CN Loss 726042 p11.2 
  Oncoscan chr6:58,213,475-58,770,502 CN Gain 557028 p11.2 - p11.1 
  Oncoscan chr6:61,886,393-170,913,051 CN Loss 109026659 q11.1 - q27 
  Oncoscan chr7:1-159,138,663 CN Gain 159138663 p22.3 - q36.3 
  Oncoscan chr7:1-159,138,663 CNN-LOH 159138663 p22.3 - q36.3 
  Oncoscan chr8:55,457,188-71,067,368 CN Loss 15610181 q11.23 - q13.3 
  Oncoscan chr9:204,738-35,809,328 CNN-LOH 35604591 p24.3 - p13.3 
  Oncoscan chr9:21,901,263-22,056,499 
Homozygous Copy 
Loss 155237 p21.3 
  Oncoscan chr11:45,810,652-46,460,038 CN Loss 649387 p11.2 
  Oncoscan chr12:189,400-8,447,618 CN Loss 8258219 p13.33 - p13.31 
  Oncoscan chr12:19,557,354-21,282,570 CN Loss 1725217 p12.3 - p12.2 
  Oncoscan chr12:21,295,612-29,285,577 CN Gain 7989966 p12.2 - p11.22 
  Oncoscan chr12:30,814,259-33,886,138 CN Gain 3071880 p11.21 - p11.1 
  Oncoscan chr12:39,204,714-70,880,468 CN Gain 31675755 q12 - q15 
  Oncoscan chr12:74,309,125-77,911,802 CN Gain 3602678 q21.1 - q21.2 
  Oncoscan chr12:79,610,263-82,677,229 CN Gain 3066967 q21.2 - q21.31 
  Oncoscan chr12:84,462,140-89,275,759 CN Loss 4813620 q21.31 - q21.33 
  Oncoscan chr12:91,825,095-94,371,476 CN Loss 2546382 q21.33 - q22 
  Oncoscan chr12:98,498,625-115,061,325 CN Gain 16562701 q23.1 - q24.21 
  Oncoscan chr12:128,397,472-133,818,115 CN Gain 5420644 q24.32 - q24.33 
  Oncoscan chr13:45,901,876-53,198,648 CN Loss 7296773 q14.13 - q14.3 
  Oncoscan chr13:58,291,792-69,716,364 CN Gain 11424573 q21.1 - q21.33 
  Oncoscan chr20:29,519,156-40,272,376 CN Loss 10753221 q11.21 - q12 
  Oncoscan chrX:1-155,270,560 CN Loss 155270560 p22.33 - q28 
#9           
  Oncoscan chr5:1-180,915,260 CN Gain 180915260 p15.33 - q35.3 
  Oncoscan chr6:204,909-52,036,300 CNN-LOH 51831392 p25.3 - p12.2 
  Oncoscan chr6:32,100,302-32,998,152 High Copy Gain 897851 p21.32 
  Oncoscan chr7:41,421-159,118,443 CN Gain 159077023 p22.3 - q36.3 
  Oncoscan chr12:1-133,851,895 CN Gain 133851895 p13.33 - q24.33 
  Oncoscan chr17:40,424,255-80,263,427 CNN-LOH 39839173 q21.2 - q25.3 
  Oncoscan chr17:62,949,100-63,165,077 
Homozygous Copy 
Loss 215978 q24.1 









#10           
  Oncoscan chr17:400,959-12,159,990 CNN-LOH 11759032 p13.3 - p12 
#11           
  SNP6 chr1:73,100,845-74,442,581 CN Gain 1341737 p31.1 
  SNP6 chr1:149,962,792-152,551,299 CN Gain 2588508 q21.2 - q21.3 
  SNP6 chr6:40,083,170-42,855,926 CN Gain 2772757 p21.2 - p21.1 
  SNP6 chr6:78,166,644-117,921,913 CN Loss 39755270 q14.1 - q22.1 
  SNP6 chr8:106,741,322-107,876,319 CN Gain 1134998 q23.1 
  SNP6 chr8:128,951,273-129,358,847 CN Gain 407575 q24.21 
  SNP6 chr9:223,542-3,003,015 CN Gain 2779474 p24.3 - p24.2 
  SNP6 chr12:0-133,851,895 CN Gain 133851896 p13.33 - q24.33 
  SNP6 chr13:56,118,024-57,280,068 CN Gain 1162045 q21.1 
  SNP6 chr13:91,986,235-92,361,312 CN Gain 375078 q31.3 
  SNP6 chr17:49,745,106-81,195,210 CNN-LOH 31450105 q21.33 - q25.3 
  SNP6 chr19:1-12,492,039 CNN-LOH 12492039 p13.3 - p13.2 
  SNP6 chr19:6,493,673-7,463,666 
Homozygous Copy 
Loss 969994 p13.3 - p13.2 
  SNP6 chr19:37,006,258-37,414,445 CN Loss 408188 q13.12 
  SNP6 chr21:14,369,207-48,129,895 CN Gain 33760689 q11.2 - q22.3 
#12           
  Oncoscan chr1:144,790,037-193,932,788 CN Gain 49142752 q21.1 - q31.3 
  Oncoscan chr2:134,242,471-139,641,542 CN Gain 5399072 q21.2 - q22.1 
  Oncoscan chr2:212,437,072-215,227,024 CN Gain 2789953 q34 
  Oncoscan chr3:63,411-60,777,554 CNN-LOH 60714144 p26.3 - p14.2 
  Oncoscan chr3:116,120,738-117,045,461 CN Loss 924724 q13.31 
  Oncoscan chr4:181,713,895-190,915,650 CN Loss 9201756 q34.3 - q35.2 
  Oncoscan chr5:38,139-1,985,845 CN Gain 1947707 p15.33 
  Oncoscan chr6:85,053,988-92,677,362 CN Gain 7623375 q14.3 - q15 
  Oncoscan chr7:88,362,639-94,444,750 CN Gain 6082112 q21.13 - q21.3 
  Oncoscan chr8:128,651,315-128,766,080 CN Gain 114766 q24.21 
  Oncoscan chr8:128,767,004-128,840,276 CN Loss 73273 q24.21 
  Oncoscan chr13:64,574,475-69,315,335 CN Gain 4740861 q21.31 - q21.33 
  Oncoscan chr17:400,959-19,497,890 CNN-LOH 19096932 p13.3 - p11.2 
  Oncoscan chr19:247,232-3,093,163 CN Gain 2845932 p13.3 












#13           
  Oncoscan chr7:41,421-24,971,213 CN Gain 24929793 p22.3 - p15.3 
  Oncoscan chrX:25,296,129-58,470,802 CN Gain 33174674 p21.3 - p11.1 
  Oncoscan chr10:567,325-135,434,303 CN Gain 134866979 p15.3 - q26.3 
  Oncoscan chr4:91,749,811-91,794,821 CN Gain 45011 q22.1 
  Oncoscan chr1:104,446,681-110,195,901 CN Gain 5749221 p21.1 - p13.3 
  Oncoscan chr1:110,200,360-110,240,929 CN Gain 40570 p13.3 
  Oncoscan chr12:189,400-133,818,115 CN Gain 133628716 p13.33 - q24.33 
  Oncoscan chr2:32,757,598-37,578,208 CN Loss 4820611 p22.3 - p22.2 
  Oncoscan chr2:121,588,532-129,317,105 CN Loss 7728574 q14.2 - q14.3 
  Oncoscan chr2:137,910,175-151,016,074 CN Loss 13105900 q22.1 - q23.3 
  Oncoscan chr2:153,153,555-160,994,348 CN Loss 7840794 q23.3 - q24.2 
  Oncoscan chr19:247,232-11,674,294 CNN-LOH 11427063 p13.3 - p13.2 
  Oncoscan chr19:6,528,235-7,104,673 
Homozygous Copy 
Loss 576439 p13.3 - p13.2 
#14           
  Oncoscan chr7:74,132,398-159,118,443 CN Gain 84986046 q11.23 - q36.3 
  Oncoscan chr11:1-60,760,530 CN Gain 60760530 p15.5 - q12.2 
  Oncoscan chr11:91,274,842-118,350,945 CN Gain 27076104 q14.3 - q23.3 
  Oncoscan chr11:118,352,769-134,938,847 CN Loss 16586079 q23.3 - q25 
#15           
  Oncoscan chr5:99,257,992-146,632,594 CN Gain 47374603 q21.1 - q32 
  Oncoscan chr6:63,365,565-123,492,278 CN Loss 60126714 q11.2 - q22.31 
  Oncoscan chr10:122,564,306-135,434,303 CN Gain 12869998 q26.12 - q26.3 
  Oncoscan chr11:93,515,058-120,717,000 CN Gain 27201943 q21 - q23.3 
  Oncoscan chr11:120,732,508-135,006,516 CN Loss 14274009 q23.3 - q25 
  Oncoscan chr12:189,400-1,896,956 CN Gain 1707557 p13.33 
  Oncoscan chr12:22,812,766-28,466,571 High Copy Gain 5653806 p12.1 - p11.22 
  Oncoscan chr12:28,476,847-64,720,693 CN Gain 36243847 p11.22 - q14.2 
  Oncoscan chr12:64,720,694-73,671,118 High Copy Gain 8950425 q14.2 - q21.1 
  Oncoscan chr13:85,803,897-99,955,533 CN Gain 14151637 q31.1 - q32.3 
  Oncoscan chr13:99,967,798-115,103,150 CN Loss 15135353 q32.3 - q34 
  Oncoscan chr16:58,143,392-90,195,538 CN Gain 32052147 q21 - q24.3 
  Oncoscan chr17:59,315,145-80,263,427 CNN-LOH 20948283 q23.2 - q25.3 
#16           
  Oncoscan chr6:83,574,391-120,108,162 CN Loss 36533772 q14.1 - q22.31 
  Oncoscan chr11:73,228,685-113,724,673 CN Gain 40495989 q13.4 - q23.2 
  Oncoscan chr11:113,733,111-120,176,979 High Copy Gain 6443869 q23.2 - q23.3 










#17      
  Oncoscan chr3:149,230,137-197,852,564 CN Gain 48622428 q25.1 - q29 
  Oncoscan chr4:77,277,624-107,631,213 CN Gain 30353590 q21.1 - q24 
  Oncoscan chr7:111,092,478-159,118,443 CN Loss 48025966 q31.1 - q36.3 
  Oncoscan chr8:172,417-33,010,693 CNN-LOH 32838277 p23.3 - p12 
  Oncoscan chr8:1-146,364,022 CN Gain 146364022 p23.3 - q24.3 
  Oncoscan chr8:58,406,216-146,292,734 CNN-LOH 87886519 q12.1 - q24.3 
  Oncoscan chr11:70,719,897-118,343,378 CN Gain 47623482 q13.4 - q23.3 
  Oncoscan chr11:118,347,020-121,053,084 High Copy Gain 2706065 q23.3 
  Oncoscan chr11:121,062,860-134,906,706 CN Loss 13843847 q23.3 - q25 
  Oncoscan chr13:79,420,211-83,071,814 High Copy Gain 3651604 q31.1 
  Oncoscan chr13:83,098,518-94,240,082 CN Gain 11141565 q31.1 - q31.3 
  Oncoscan chr13:94,251,808-115,103,150 CN Loss 20851343 q31.3 - q34 
  Oncoscan chr15:74,343,354-102,397,317 CN Gain 28053964 q24.1 - q26.3 
  Oncoscan chr17:7,536,527-7,619,668 CN Loss 83142 p13.1 
  Oncoscan chr18:33,243,441-55,865,613 CN Gain 22622173 
q12.2 - 
q21.31 
  Oncoscan chr18:55,893,217-78,007,784 CN Loss 22114568 q21.31 - q23 






Supplementary Table S7. List of somatic mutations in BLL-11q including prediction of 
amino acid changes that affect protein function (MA, SIFT, Polyphen2, CADD).   




Supplementary Table S8. Mutational patterns across different germinal center derived lymphoma 
subgroups including BL,21,22 DLBCL,5,23 DH/TH,24,25 and HGBCL, NOS with or without MYC 
rearrangement.25 The BL pattern includes mutations in BL-associated genes and the GCB-DLBCL pattern 
includes mutations associated with GCB phenotype according to literature. BLL-11q mutational pattern 









HGBCL DH/TH  
n=44 
HGBCL with or 




(%) (%) (%) (%) (%) 
BLL-11q 
BTG2 40 4.8* - - 0* 
ETS1 30 1.2* - - 0* 
EP300 30 6* 6.8 0 0* 
Burkitt 
Lymphoma 
ID3 0 0 25 88.9* 59.4* 
TCF3 0 0 4.5 0 31.3 
CCND3 0 3,6 29.2b 22.2 9.4 
MYC 20 2.4 43.2 44.4 71.9* 
DDX3X 30 0a* - - 31.3 
GCB-
DLBCL 
KMT2D 20 32.5 60c - 6.3 
CREBBP 20 25.3 50 44.4 6.3 
TNFRSF14 0 20.5 20c - 0 
B2M 0 20.5 10c - 0 
EZH2 10 21.7 27.3 0 0 
GNA13 30 21.7 15c - 9.4 
FOXO1 10 13.3 30c - 6.3 
ACTB 0 13.3 - - 0 
SOCS1 0 15.7 30c - 0 
* Significant differences of mutated gene prevalence between BLL-11q series and the other germinal 
center entities (P<0.05). 
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